GrinsztejnB, NguyenB-Y, KatlamaCet al.Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomized controlled trial. Lancet, 2007; 369:1261–1269.
2.
MarkowitzM, NguyenB-Y, GotuzzoEet al.Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naïve patients with HIV-1 infection. J Acquir Immune Defic Syndr, 2007; 46:125–133.
3.
CooperDA, GatellJ, RockstrohJet al.48-week results from BENCHMRK-1, a Phase III study of raltegravir in patients failing antiretroviral therapy with tripleclass resistant HIV-1 [abstract 788]15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February3–6, 2008.
4.
SteigbigelR, KumarP, EronJet al.48-week results from BENCHMRK-2, a Phase III study of raltegravir in patients failing antiretroviral therapy with tripleclass resistant HIV-1 [Abstract 789]15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February3–6, 2008.
5.
SteigbigelRT, CooperDA, KumarPNet al.Supplement to Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med, 2008; 359:339–354.
6.
HarrisM, LarsenG, MontanerJ. Excacerbation of depression associated with starting raltegravir: A report of four cases. AIDS, 2008; 22:1885–1896.
7.
ReidS, DwyerJ. Insomnia in HIV infection: A systematic review of prevalence, correlates, and management. Psychosom Med, 2005; 67:260–269.
8.
DarkoD, MitlerM, MillerJ. Growth hormone, fatigue, poor sleep, and disability in HIV infection. Neuroendocrinology, 1998; 67:317–324.
9.
RubinsteinM, SelwynP. High prevalence of insomnia in an outpatient population with HIV infection. J Acquired Immune Defic Syndr Hum Retrovirol, 1998; 19:260–265.
10.
RobbinsJ, PhillipsK, DudgeonW, HandG. Physiological and psychological correlates of sleep in HIV infection. Clin Nurs Res, 2004; 13:33–52.
